

The Inaugural ICODA Forum – Thursday 19 November – Breakout Session Information

	Breakout 1: Safety and efficacy of medicines (Driver Project 1)	Breakout 2: International Perinatal Outcomes in the Pandemic Study (iPOP) – How Team Science is Changing the Research Landscape (Driver Project 2)	Breakout 3: Understanding the global landscape of data initiatives: Mapping and collaborating	Breakout 4: Public and patient involvement and engagement at a Global Level
Participants	<ul style="list-style-type: none"> Phil Ambery, AstraZeneca Jonas Haggstrom, Cytel Benjamin Kramer, Genentech Jaap Mandema, Certara Peter Mesenbrink, Novartis Nevine Zariffa, NMD Group 	<ul style="list-style-type: none"> Meghan Azad, Merilee Brockway, Natalie Rodriguez, University of Manitoba Livia Nagy, Patient Representative Aziz Sheikh, Sarah Stock University of Edinburgh 	<ul style="list-style-type: none"> Steven Kern, Bill & Melinda Gates Foundation Nicola Perrin, ICODA Marta Tufet, UK Collaborative on Development Research Anne Wozencraft, ICODA 	<ul style="list-style-type: none"> Julia Levy, ICODA Andrew Morris, Health Data Research UK Helen Parks, European Lung Foundation Bella Starling, Vocal
Session Objectives	<p>To share progress of this Driver Project focusing on Safety and Efficacy of Medicines to:</p> <ul style="list-style-type: none"> Understand and demonstrate the data assets and tools available to us now, and over the next 6 months Mobilise the research community to become advocates of data sharing Establish data research teams across the community 	<p>To demonstrate the rapid trajectory and evolution of the International Perinatal Outcomes in the Pandemic (IPOP) Study to:</p> <ul style="list-style-type: none"> Illustrate how integration of varying areas of expertise lead to truly translational science. Define the concepts of Team Science, open and transparent communication, and collaboration in large scale international projects. Demonstrate how Team Science is changing the landscape for conducting research. Highlight key considerations, tools and platforms critical to large scale study success. 	<p>To provide insights into the complex COVID-19 data landscape by sharing:</p> <ul style="list-style-type: none"> An update from UKCDR on their living systematic review of COVID-related studies An update from ICODA on a recent mapping exercise to build understanding of COVID-19 data-related activities A panel discussion to explore ways to collaborate to provide an up-to-date overview of the COVID-19 data landscape, in order to improve coordination across the COVID-19 community. 	<p>To explore the role and importance of ensuring meaningful Public and Patient involvement and community engagement (PPIE) and the challenges of delivering this for a global initiative:</p> <ul style="list-style-type: none"> Share our approach to co-creating our PPIE strategy with experts from around the global public and patient community and lay representatives Seek additional input from attendees to further inform our strategy Set out our commitment and plans for continued engagement in our governance and ways of working

The Inaugural ICODA Forum – Thursday 19 November – Breakout Session Information

<p>Session Overview</p>	<p>This session will focus on the work of ICODA's first driver project, summarising the data from key trials and publicly available data sources to understand the treatments of COVID19.</p> <ul style="list-style-type: none"> • First, the team will present the possibilities within the CODEX workbench with data assets and tools available. • Next, several experts will discuss the challenges the community currently faces and the approach they're taking to solve them. 	<p>This session will focus on the iPOP study. The panel will discuss how the study was developed and the process for evolving it into what it is today.</p> <ul style="list-style-type: none"> • Video: Intro to iPOP from the Core Team • Study overview, progress and current status • Overview of the Team Science approach, what it means and how it differs from traditional research approaches • Highlight of the importance of Knowledge Users and Participant Engagement –Tips, Tools and Tricks for large scale collaborations 	<p>There has been a huge investment in research to tackle COVID-19 in the last six months, and more than 2000 trials are now underway. An ever-increasing amount of relevant data is therefore being generated and collected, and a large number of COVID-19 data-related collaborations and initiatives have also begun.</p> <p>The landscape of COVID-19 data-related activities is busy and complex. It is often difficult to know what is happening, and there is a real need for collaboration and coordination to avoid duplication.</p>	<p>This section will focus on the importance of PPIE and work done to date to develop a meaningful PPIE strategy for ICODA. It will include:</p> <ul style="list-style-type: none"> • Why public and patient involvement and engagement is so important to ICODA • A patient perspective • The challenges of delivering meaningful PPIE at a global scale • ICODA's approach to date including sharing highlights of a recent workshop with experts from around the world • A panel discussion • Next steps
<p>Potential interest to...</p>	<p>Researchers, data analysts, Clinical scientists, Data scientists, Clinicians</p>	<p>Big Data, Translational Researchers, Knowledge Users and PPIE, Research in LMIC, Clinical researchers Epidemiologists, Public Health Researchers, Environmental Sciences</p>	<p>Policy makers, patients and representatives from the public, public health researchers</p>	<p>Researchers, policy makers, patients and representatives from the public – anyone interested in ensuring that our work reflects the priorities and concerns of the patient and public community around the world.</p>